How is Trillium Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts? A "buy" rating indicates that analysts believe TRIL will outperform the market and that investors should add to their positions of Trillium Therapeutics. This browser is no longer supported at MarketWatch. We employ biologic and small molecule-based approaches that enhance the ability of the patient’s own immune system … Intraday data delayed at least 15 minutes or per exchange requirements. Forecasted annual earnings growth. Trillium Therapeutics Inc. analyst ratings, historical stock prices, earnings estimates & actuals. Institutions hold 68.87% of the Float. By using this site you agree to the TTI-622 is Trillium’s second SIRPαFc fusion protein. Log in to see them here or sign up to get started. james@trilliumtherapeutics.com. TRIL.CA updated stock price target summary. Trillium does not, by its reference above, imply its endorsement of or concurrence with such information, conclusions or recommendations. Evercore ISI initiates coverage on Trillium Therapeutics (NASDAQ: TRIL) with a Outperform rating. They set an “outperform” rating and a $28.00 price target on the stock. For the best MarketWatch.com experience, please update to a modern browser. Amount of Analyst Coverage Trillium Therapeutics has received no research coverage in the past 90 days. TTI-622 consists of the same extracellular CD47-binding domain of human SIRPα as TTI-621 but has an IgG4 Fc region instead of an IgG1 Fc. The company’s shares closed last Monday at $5.22. The analyst commented, "We initiate coverage of Trillium Therapeutics with a Market Outperform rating and $10 price target, based on a discounted EPS and revenue multiple analysis. Cambridge, MA 02140 TTI-621 is a potent dual function molecule that is designed to inhibit CD47 on the tumor cell and simultaneously deliver a strong activating signal to the immune system, whereas most competitor CD47 blockers require a second drug for full activation. According to analysts' consensus price target of C$25.00, Trillium Therapeutics has a forecasted upside of 67.3% from its current price of C$14.94. Create a list of the investments you want to track. The shares outstanding are 100.71M, and float is at 83.86M with Short Float at 10.62%. Tel: +1 416.595.0627, James Parsons Shares of NASDAQ:TRIL opened at $6.78 on Tuesday. Visit a quote page and your recently viewed tickers will be displayed here. Trillium is followed by the analysts listed above. Chief Financial Officer Following recent promising clinical data updates and after raising over $300 million in 2020, the Company is now embarking on a substantial organizational scale-up to initiate a phase 2 program across a range of cancer indications. Olo, maker of restaurant-ordering tech, shares pop 28% in IPO, Dow trades fractionally higher, but Nasdaq slides ahead of Fed decision, Amazon jumps into health care, will provide telemedicine service to employers nationwide, Amid vaccine hurdles, EU battles to save summer vacations with COVID travel pass, Auto Parts Stocks Can Shift Higher, Analyst Says, Bond king Bill Gross says he made $10 million shorting GameStop, WHO urges countries to keep using AstraZeneca vaccine as ‘benefits outweigh risks’, COVID-19 vaccines get an endorsement from Trump, as daily U.S. deaths rise back above 1,000, Eviction filings increased after CDC issued nationwide moratorium, government report shows, TRIL will report 2020 earnings on 03/08/2022, TRIL will report Q4 2020 earnings on 05/07/2021. Cowen & Co. analyst Boris Peaker maintained a Buy rating on Trillium Therapeutics today. Bloom Burton cut Trillium Therapeutics from a "buy" rating to an "accumulate" rating … 100 Cambridgepark Drive, Suite 510 Cambridge, MA 02140 USA Tel: +1 857.412.7029 Please note that any opinions, estimates or forecasts regarding Trillium's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Trillium or its management. 100 Cambridgepark Drive, Suite 510 Cambridge, MA 02140 USA Tel: +1 857.412.7029 Have Watchlists? Mississauga, ON L5L 1J9 100 Cambridgepark Drive, Suite 510 Cambridge, MA 02140 USA Tel: +1 857.412.7029 Trillium Therapeutics presently has a consensus rating of Buy and a consensus price target of $7.13. The company’s shares closed last Monday at $3.92. Tel: +1 416.595.0627 x232 Trillium Therapeutics currently has 1 hold rating and 4 buy ratings from Wall Street analysts. Cambridge Office. 47.7%. Evercore ISI started coverage on shares of Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) in a research report report published on Monday, Benzinga reports. Cambridge Office. Cowen & Co. analyst Boris Peaker maintained a Buy rating on Trillium Therapeutics (TRIL – Research Report) today. Historical and current end-of-day data provided by FACTSET. Trillium Therapeutics Inc TRIL ... are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst … Evercore uses cookies to give you the best experience on our website. Finally, Evercore ISI assumed coverage on shares of Trillium Therapeutics in a research note on Monday, October 12th. To add more color to this target, the company’s high over the last year is $16.89 and the low is $0.24. Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies … Some of the cookies we use are essential for parts of the website to operate and cannot be switched off in our systems. Find the latest Trillium Therapeutics Inc. (TRIL) stock quote, history, news and other vital information to help you with your stock trading and investing. Cambridge Office. 141 institutions hold shares in Trillium Therapeutics Inc. (TRIL), with institutional investors hold 68.87% of the company’s shares. USA The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $21.25. ... Future Dividend Coverage: ... Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of … Their average twelve-month price target is $21.25, predicting that the stock has a possible upside of 76.64%. Trillium Therapeutics is a clinical stage immuno-oncology company based in Cambridge, MA and Toronto, ON. Subscriber Agreement & Terms of Use, A number of other equities research analysts have also recently commented on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. Trillium Therapeutics Inc. (TRIL) shares are trading at lower $14.97 and the avg recommendation for the stock is Strong Buy, while the current analyst price target stands at $11.02. The stock has a consensus analyst rating of "Buy." Intraday Data provided by FACTSET and subject to terms of use. Trillium Therapeutics Inc. analyst estimates, including TRIL earnings per share estimates and analyst recommendations. Institutions hold 68.87% of the Float. Please note that any opinions, estimates or forecasts regarding Trillium's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Trillium … View the latest ratings for TRIL. Summary. Privacy Notice, and All quotes are in local exchange time. 5 Wall Street analysts have issued ratings and price targets for Trillium Therapeutics in the last 12 months. Trillium Therapeutics has a 1-year low of $0.24 and a 1-year high of $7.97. Trillium Therapeutics is an immuno-oncology company developing innovative therapies for the treatment of cancer. Analyst Coverage Trillium is followed by the analysts listed above. Trillium Therapeutics (TRIL +2.3%) opens higher after Evercore ISI launches coverage at Outperform with a Street-high $28 price target, and a $60 bull case if Trillium … Several brokerages recently commented on TRIL. There are currently no items in this Watchlist. The shares outstanding are 100.71M, and float is at 83.86M with Short Float at 10.62%. 100 Cambridgepark Drive, Suite 510 Cambridge, MA 02140 USA Tel: +1 857.412.7029 Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. The firm issued an outperform rating and a $28.00 price target on the biotechnology company’s stock. 141 institutions hold shares in Trillium Therapeutics Inc. (TRIL), with institutional investors hold 68.87% of the company’s shares. Copyright © 2021 MarketWatch, Inc. All rights reserved. The company’s shares closed last Monday at $3.92. The stock has a market capitalization of $477.08 million, a price-to-earnings ratio of -3.37 and a beta of 2.05. Tel: +1 857.412.7029, 2488 Dunwin Drive Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. According to TipRanks.com , Peaker is a 4-star analyst with an average return of 4.4% and a 41.6% success rate. Canada According to TipRanks.com, Peaker is a 2-star analyst with an average return of -0.2% Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. 100 Cambridgepark Drive, Suite 510 Cookie Notice (). The Company’s two clinical programs, TTI-621 and TTI-622, target CD47, a “don’t eat me” signal that cancer cells frequently use to evade the immune system. See Trillium Therapeutics Inc. (TRIL) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Something went wrong while loading Watchlist. Find the latest analyst research for Trillium Therapeutics Inc. Common Shares (TRIL) at Nasdaq.com.
Why Sift Is Invariant To Rotation And Scale, Evolve Training Center Facebook, Ellen Grace Philpotts-page Net Worth, Gun Attachments List, Shediac Weather Network, Asigurare Auto Uk Verificare, 360 Graden Feedback Voorbeeld Antwoorden,